Medical Crossfire®: Navigating the Advent of Novel Targeted and Immunotherapeutic Approaches in Cholangiocarcinoma

Release Date: February 19, 2021
Expiration Date: February 19, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the treatment of cholangiocarcinoma. Novel targets based on understanding of tumor biology and pathophysiology have already shifted treatment paradigms for patients with specific biomarkers, such as mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), fibroblast growth factor receptor (FGFR), microsatellite instability-high (MSI-H), and other mutated genes. In this educational program, these experts explore the latest data regarding unmet needs, advances in pathophysiology, and emerging therapeutic strategies for the management of cholangiocarcinoma across lines of care. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with cholangiocarcinoma.

This educational activity is an archive of the live virtual symposium held on January 16, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., and Incyte Corporation.

Target Audience

This educational program is directed toward a global audience of medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of cholangiocarcinoma. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cholangiocarcinoma are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the biologic rationale that has informed recent clinical development of targeted and immunotherapeutic approaches for cholangiocarcinoma
• Integrate key genomic and molecular testing strategies that allow for cholangiocarcinoma tumor characterization and inform decision-making for patients with these tumors
• Apply practice-changing evidence on novel immunotherapies and targeted therapies to clinical scenarios encountered in cholangiocarcinoma management
• Promulgate multidisciplinary approaches to identify and mitigate the impact of treatment-related toxicities in the care of patients with cholangiocarcinoma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Andrew X. Zhu, MD, PhD
Director Emeritus, Liver Cancer Research
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
Director, Jiahui International Cancer Center
Shanghai, China

Disclosures: Consultant: Bayer, Eisai, Exelixis, Lilly, Merck, Roche, Sanofi.

Tanios Bekaii-Saab, MD, FACP
Professor
Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic AZ, USA
Consortium Chair, ACCRU
Phoenix, AZ

Disclosures: Grant Research Support: Research Funding (to institution): Agios, Arys, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Array Biopharma, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, Bristol Myers Squibb; Consultant: Consulting (to institution): Ipsen, Array Biopharma, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte and Merck. Consulting (to self): Boehringer Ingelheim, Janssen, Eisai, Daiichi Sankyo, Natera, TreosBio, Celularity, Exact Science and Sobi; Other: IDMC/DSMB (to self): Astra Zeneca, Exelixis, Lilly, PanCan and 1Globe. Scientific Advisory Board: Imugene, Immuneering and Sun Pharma Inventions/Patents: WO/2018/183488 and WO/2019/055687.

Rondell P. Graham, MBBS
Associate Professor, Gastrointestinal/Liver Pathology
Molecular Pathology, Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Disclosures: Rondell P. Graham has no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.